Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA7 | P43166 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20184188 | 0.95 | KMT2A (0.68) | KMT2AATMALDH1A1MEN1KDM4E | |
| Cadaverine Tartrate SCHEMBL29125517 | 0.92 | KMT2A (0.63) | KMT2AATMALDH1A1MEN1KDM4E | |
| SCHEMBL14860179 | 0.89 | KMT2A (0.59) | KMT2AATMALDH1A1MEN1KDM4E | |
| SCHEMBL20381852 | 0.88 | KMT2A (0.59) | KMT2AATMALDH1A1MEN1KDM4E | |
| SCHEMBL14859632 | 0.87 | HRH3 (0.64) | KMT2AALDH1A1MEN1KDM4EMAPT | |
| SCHEMBL12222589 | 0.86 | ALDH1A1 (0.56) | KMT2AATMALDH1A1MEN1KDM4E | |
| SCHEMBL14860115 | 0.86 | SIGMAR1 (0.61) | KMT2AATMALDH1A1MEN1KDM4E | |
| SCHEMBL6863535 | 0.85 | KMT2A (0.68) | KMT2AATMALDH1A1MEN1KDM4E | |
| SCHEMBL15372378 | 0.84 | KMT2A (1.00) | KMT2AALDH1A1MEN1MAPTLMNA | |
| SCHEMBL14860509 | 0.84 | KMT2A (0.63) | KMT2AALDH1A1MEN1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024378-A | N' - [ (3-allyl-2-hydroxyphenyl) methylene ] -2- (4-benzyl-1-piperazinyl) acethydrazide tartrate crystal, and preparation method and application thereof | 北京科佑爱科技有限责任公司 | 2023-11-10 | — | — | CN | claimed |
| CN-117024378-A | N' - [ (3-allyl-2-hydroxyphenyl) methylene ] -2- (4-benzyl-1-piperazinyl) acethydrazide tartrate crystal, and preparation method and application thereof | 北京科佑爱科技有限责任公司 | 2023-11-10 | — | — | CN | disclosed |
| US-11612598-B2 | Compounds and methods for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-03-28 | — | — | US | disclosed |
| EP-1893210-B1 | SELECTIVE APOPTOTIC INDUCTION IN CANCER CELLS INCLUDING ACTIVATION OF PROCASPASE-3 | UNIV ILLINOIS (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190201394-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-07-04 | — | — | US | disclosed |
| US-10166229-B2 | Compounds and methods for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-01-01 | — | — | US | disclosed |
| US-9643960-B2 | Procaspase activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643960-B2 | Procaspase activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| US-20170105989-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170105989-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-04-20 | — | — | US | disclosed |
| US-20110257398-A1 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2010091382-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-08-12 | — | — | WO | disclosed |
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| WO-2008134474-A2 | COMPOSITIONS AND METHODS INCLUDING CELL DEATH INDUCERS AND PROCASPASE ACTIVATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20070049602-A1 | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049602-A1 | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-03-01 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049602-A1 | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 | CASP3, CASP7, CASP6 | KMT2A 4674/4885ATM 953/4885ALDH1A1 2091/4885 |
| US-20110257398-A1 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation | CASP3, CASP6, CASP5 | KMT2A 3246/4885ATM 2086/4885ALDH1A1 2167/4885 |
| US-10166229-B2 | Compounds and methods for the treatment of cancer | CASP3, CASP6, CASP5 | KMT2A 1515/4885ATM 1532/4885ALDH1A1 926/4885 |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | KMT2A 4034/4885ATM 107/4885ALDH1A1 3165/4885 |
| US-20190201394-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | CASP3, BAX, CASP6 | KMT2A 3132/4885ATM 625/4885ALDH1A1 1106/4885 |
| US-20170105989-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | CASP3, CASP6, CASP5 | KMT2A 1515/4885ATM 1532/4885ALDH1A1 926/4885 |
| US-11612598-B2 | Compounds and methods for the treatment of cancer | CASP3, BAX, CASP6 | KMT2A 3132/4885ATM 625/4885ALDH1A1 1106/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | KMT2A 4112/4885ATM 126/4885ALDH1A1 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.